OrthoPediatrics Corp. Files 8-K for Material Agreement

TL;DR

OrthoPediatrics Corp. signed a big deal and sold some stock, creating new debt.

AI Summary

On August 12, 2024, OrthoPediatrics Corp. entered into a material definitive agreement, which also created a direct financial obligation. The filing also disclosed unregistered sales of equity securities. Specific details regarding the agreement, financial obligation, and equity sales were not provided in the excerpt.

Why It Matters

This filing indicates significant corporate activity, including a new financial obligation and equity transactions, which could impact the company's financial structure and shareholder value.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement and a direct financial obligation, suggesting potential financial risks or opportunities that require further investigation.

Key Players & Entities

• OrthoPediatrics Corp. (company) — Registrant
• August 12, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.00025 — ge on which registered Common Stock, $0.00025 par value per share KIDS Nasdaq Glo
• $25,000,000 — sociation, as agent, was closed and the $25,000,000 Initial Term Loan Commitment was funded
• $50.0 million — on August 12, 2024, the Company issued $50.0 million in aggregate principal amount of the Co
• $1,000 — e of 33.8294 shares of common stock per $1,000 principal amount of Notes, which is sub

Filing Documents

• tm2421268d1_8k.htm (8-K) — 34KB
• tm2421268d1_ex4-1.htm (EX-4.1) — 771KB
• tm2421268d1_ex4-2.htm (EX-4.2) — 74KB
• tm2421268d1img_001.jpg (GRAPHIC) — 2KB
• tm2421268d1img_002.jpg (GRAPHIC) — 3KB
• tm2421268d1img_003.jpg (GRAPHIC) — 3KB
• tm2421268d1img_004.jpg (GRAPHIC) — 3KB
• tm2421268d1img_005.jpg (GRAPHIC) — 2KB
• tm2421268d1img_006.jpg (GRAPHIC) — 4KB
• 0001104659-24-088333.txt ( ) — 1205KB
• kids-20240812.xsd (EX-101.SCH) — 3KB
• kids-20240812_lab.xml (EX-101.LAB) — 33KB
• kids-20240812_pre.xml (EX-101.PRE) — 22KB
• tm2421268d1_8k_htm.xml (XML) — 3KB

01 ENTRY INTO OR AMENDMENT OF A MATERIAL DEFINITIVE AGREEMENT

ITEM 1.01 ENTRY INTO OR AMENDMENT OF A MATERIAL DEFINITIVE AGREEMENT. Term Loan Agreement On August 12, 2024, the previously announced Credit Agreement and Guaranty (the "Term Loan Agreement"), dated August 5, 2024, by and among OrthoPediatrics Corp. (the "Company") and its wholly owned domestic subsidiaries, as borrowers, one or more funds managed by Braidwell LP, as lenders, and Wilmington Trust, National Association, as agent, was closed and the $25,000,000 Initial Term Loan Commitment was funded. Indenture and Convertible Notes Also on August 12, 2024, the Company issued $50.0 million in aggregate principal amount of the Company's 4.75% Convertible Senior Notes due February 15, 2030 (the "Notes") pursuant to the previously announced Purchase Agreement (the "Purchase Agreement"), dated August 5, 2024, by and between the Company and Braidwell Transaction Holdings LLC – Series 10 (the "Purchaser"). The Notes were issued pursuant to, and are governed by, an indenture (the "Indenture"), dated as of August 12, 2024, between the Company and U.S. Bank Trust Company, National Association, as trustee (the "Trustee"). The Indenture and form of Notes are also filed as Exhibits 4.1 and 4.2 hereto, and are incorporated herein by reference. The terms and conditions of the Term Loan Agreement, Purchase Agreement, Indenture and Notes are summarized in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on August 5, 2024.

03 Creation of a Direct Financial Obligation or an Obligation

ITEM 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth in

01 above is incorporated by reference into this Item 2.03

Item 1.01 above is incorporated by reference into this Item 2.03.

02 UNREGISTERED SALES OF EQUITY SECURITIES

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES. The disclosure set forth in Item 1.01 above is incorporated by reference into this Item 3.02. The Notes were issued to the Purchaser in reliance upon Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act") in a transaction not involving any public offering. For the first twelve (12) months following the purchase, the Notes may only be resold by the Purchaser to persons whom the Purchaser reasonably believes are "qualified institutional buyers," as defined in, and in accordance with, Rule 144A under the Securities Act. Any shares of the Company's common stock that may be issued upon conversion of the Notes will be issued in reliance upon Section 3(a)(9) of the Securities Act as involving an exchange by the Company exclusively with its security holders. Initially, a maximum of 1,691,470 shares of the Company's common stock may be issued upon conversion of the Notes, based on the initial maximum conversion rate of 33.8294 shares of common stock per $1,000 principal amount of Notes, which is subject to customary anti-dilution adjustment provisions.

01 FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (d)Exhibits. Exhibit No. Description of Exhibit 4.1 Indenture, dated as of August 12, 2024, between OrthoPediatrics Corp. and U.S. Bank Trust Company, National Association, as trustee 4.2 Form of 4.75% Convertible Senior Notes due February 15, 2030 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * * * * * * SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 12, 2024 OrthoPediatrics Corp. By: /s/ Daniel J. Gerritzen Daniel J. Gerritzen, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR